RxDoctor Payments Data

Binh Nguyen, MD

Ophthalmology · Munster, INNPI 1013910223

Payments from drug & device makers

$3,334in general payments, 2019–2025

Across 109 payments — averaging $30.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$611
  • AbbVie$519
  • Bausch & Lomb Americas Inc.$478
  • Johnson & Johnson Surgical Vision, Inc.$339
  • Alcon$311
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$273
  • plus $804 from 15 others

What the payments were for

  • Food & beverage$3,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,334 in reported general payments places this provider in the 70th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$377,449
Medicare patients
1,253
Services billed
3,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine68$80,042
LumiganBimatoprost77$42,444
XiidraLifitegrast17$33,101
Cyclosporine26$15,190
CombiganBrimonidine Tartrate/Timolol34$13,111
VyzultaLatanoprostene Bunod20$11,172
Travoprost95$11,009
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol54$5,747
Cosopt PfDorzolamide/Timolol/Pf23$4,882
Prednisolone Acetate198$4,823
Latanoprost584$4,240
Ketorolac Tromethamine293$3,625
MoxifloxacinMoxifloxacin Hcl118$2,579
Timolol Maleate178$2,114
Tobramycin-DexamethasoneTobramycin/Dexamethasone27$1,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$519$135,597179 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$478$44,27337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →